title: Elevated amniotic fluid F₂-isoprostane: a potential predictive marker for preeclampsia.
abstract: In the complex mechanism of preeclampsia, oxidative stress is an important pathogenic factor, and F₂-isoprostane is a marker of oxidative stress and lipid peroxidation. The objective of this study was to identify if the amniotic fluid (AF) levels of F₂-isoprostanes were elevated in women who later developed preeclampsia. In this study, we analyzed AF F₂-isoprostane concentrations with enzyme immunoassay (EIA), and the EIA results could be validated by quantitative mass spectrometry. The mean AF concentration of F₂-isoprostanes was significantly higher in pregnancies with subsequent development of preeclampsia (123.1 ± 57.6 pg/ml, n = 85) than in controls (73.8 ± 36.6 pg/ml, n = 85). The AF elevation of F₂-isoprostanes was even higher in the preeclampsia with intrauterine growth restriction group (138.3 ± 65.2 pg/ml, n = 39). The area under the curve of the receiver operating characteristics analysis for AF F₂-isoprostanes assay was 0.81, supporting its potential as a biomarker for preeclampsia. These results indicate that oxidative stress existed before the onset of clinical preeclampsia, further suggesting that the elevation of AF F₂-isoprostanes may be used as a guide for antioxidant supplementation to reduce the risk and/or severity of preeclampsia.
authors.affiliation: Department of Obstetrics and Gynecology, Lin-Kou Medical Center, Chang Gung Memorial Hospital School of Medicine, Chang Gung University, Tao-Yuan 333, Taiwan.
authors.forename: Chao-Nin
authors.initials: CN
authors.lastname: Wang
authors.forename: Jannie Ying-Syuan
authors.initials: JY
authors.lastname: Chen
authors.forename: Sahadevan
authors.initials: S
authors.lastname: Sabu
authors.forename: Yao-Lung
authors.initials: YL
authors.lastname: Chang
authors.forename: Shuenn-Dyh
authors.initials: SD
authors.lastname: Chang
authors.forename: Chuan-Chi
authors.initials: CC
authors.lastname: Kao
authors.forename: Hsiu-Huei
authors.initials: HH
authors.lastname: Peng
authors.forename: Ho-Yen
authors.initials: HY
authors.lastname: Chueh
authors.forename: An-Shine
authors.initials: AS
authors.lastname: Chao
authors.forename: Po-Jen
authors.initials: PJ
authors.lastname: Cheng
authors.forename: Yun-Shien
authors.initials: YS
authors.lastname: Lee
authors.forename: Lang-Ming
authors.initials: LM
authors.lastname: Chi
authors.forename: Tzu-Hao
authors.initials: TH
authors.lastname: Wang
mesh_terms: D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry*; D000975:Antioxidants / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D001835:Body Weight; D016022:Case-Control Studies; D002853:Chromatography, Liquid; D028441:F2-Isoprostanes / Q000032:analysis* / Q000378:metabolism; D005260:Female; D005333:Fetus; D006801:Humans; D007124:Immunoenzyme Techniques; D007231:Infant, Newborn; D015227:Lipid Peroxidation; D013058:Mass Spectrometry; D018384:Oxidative Stress; D011225:Pre-Eclampsia / Q000378:metabolism* / Q000503:physiopathology / Q000517:prevention & control; D011237:Predictive Value of Tests; D011247:Pregnancy; D012372:ROC Curve; D012306:Risk
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D028441:F2-Isoprostanes